News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Schering-Plough Corporation (SGP): Appoints Geri Brouwers General Manager Of Schering-Plough Belgium/Luxembourg



10/19/2005 5:11:47 PM

KENILWORTH, N.J., Oct. 7 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that Geri Brouwers has been named general manager, Schering-Plough, Belgium and Luxembourg, effective immediately. He will be based in Brussels and will report to Gilles Picard, vice president of Europe, Area 1, which includes Switzerland, Portugal, Norway, Denmark, Netherlands, Sweden, Greece, Finland, Austria and Belgium/Luxembourg. Brouwers succeeds Bruno Raynal who has been appointed head of the immunology business unit, Schering-Plough France.

Brouwers has held various management-level positions in the pharmaceutical industry. Most recently, he was general manager of Pharmacia Corporation in Belgium. Prior to his position with Pharmacia, he held positions of increasing responsibility with Wellcome and Glaxo-Wellcome in Belgium, London and Denmark and was general manager of Continental Pharma/Searle, the pharmaceutical branch of Monsanto Corporation in Belgium and Luxembourg.

Brouwers has been involved in multiple organizational change or structural re-engineering efforts in market country operations as well as in mergers and acquisitions in Belgium and abroad. He has been involved in global strategic brand responsibilities, including biotechnology.

Brouwers holds a doctorate degree in Veterinary Medicine (DVM) from the University of Ghent, Belgium.

"This change is designed to build leadership and strength for the New Schering-Plough in Europe," said Apet Iskenderian, president, Europe, Canada, Middle East and Africa, for Schering-Plough. "We are pleased to welcome Geri Brouwers to our company."

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 30,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com/.

Schering-Plough Corporation

CONTACT: Investor Contact: Alex Kelly or Janet Barth, +1-908-298-7463,or Media Contact: Gail Thornton, +1-908-298-5313, all of Schering-PloughCorporation


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES